Regentys
Business Services · Florida, United States · 1-10 Employees
View Company Info for Free
Overview
Headquarters
6135 NW 167th St Ste E15, Hialeah, Flori...Phone Number
(844) 432-7262Website
www.regentys.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
1
1
1
1
1
1
About Regentys
Founded in 2013, Regentys is headquartered in Miami Lakes, Florida. They are a development stage, regenerative medicine company focused on developing treatments for patients with gastrointestinal disorders.Explore more
Regentys Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Regentys your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check out if Regentys is spiking on competitors!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Congratulate Masked Content for being promoted to Masked Content at Regentys
Check if Regentys has recently received funding, and reach out quickly before it becomes old news!
Regentys, which may be a good buyer, showed buying intent in Masked Content Topic
Funding: Get notified immidiatlly once Regentys has new funding data
Website visits: Recent activity has been detected on your website
Click to see if Regentys had a recent Job posting/layoffs
Earning: See what the market has to say on Regentys recently announced quarterly report
Product Launch: Get notified when Regentys launches new products
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 3 more new buyers
Compare Similar Companies to Regentys
Compare insights from companies similar to Regentys, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Regentys is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Regentys is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Regentys.
Regentys financials insights
Gather financial insights about Regentys, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2016
Private Equity
$1.5M
Regentys Tech Stack
A closer look at the technologies used by Regentys
Regentys News & Media
Generex Biotechnology Completes Acquisition of Regentys Corporation
MIRAMAR, Fla.--(BUSINESS WIRE)--Generex Biotechnology Corporation (OTCQB:GNBT) is pleased to announce that the company has completed the acquisition of 51% of Regentys™ Corporation, a regenerative medicine company focused on developing novel treatments for patients with gastrointestinal (GI) disorders. The terms of the deal include the previously reported upfront payment of $400,000, plus $14.6 million to be paid according to a milestone-based schedule. Details of the transaction can be found iGenerex Biotechnology Partner Regentys Corporation Receives European Patent Approval for ECMH™ for Treatment of Ulcerative Colitis
MIRAMAR, Fla.--(BUSINESS WIRE)--Generex Biotechnology Corporation (OTCQB:GNBT) announced today that Regentys Corporation (formerly Asana Medical, Inc.), a clinical stage regenerative medicine company contracted to become a subsidiary of Generex, was granted European Patent No. 2983616 entitled “Method And Composition For Treating Inflammatory Bowel Disease Without Colectomy.” The Company's patent secures market exclusivity for its key product. Regentys ECMH™ is a novel application of extracelluGenerex Biotechnology Expands Medical Device & Wound Care Portfolio with Acquisition of Regentys Corporation
MIRAMAR, Fla.--(BUSINESS WIRE)--Generex Biotechnology Corporation (OTCMKTS:GNBT) is pleased to announce that the company has signed a Binding Letter of Intent to acquire 51% of Regentys Corporation, a regenerative medicine company focused on developing treatments for patients with gastrointestinal (GI) disorders. The company’s first product, Regentys Extra-Cellular Matrix Hydrogel, is a first-in-class, non-pharmacologic, non-surgical treatment option for patients suffering from Ulcerative Colit
Read more news
Top Business Services Companies
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Regentys
Sign Up For FreeTo access detailed company insights
Founded in 2013, Regentys is headquartered in Miami Lakes, Florida. They are a development stage, regenerative medicine company focused on developing treatments for patients with gastrointestinal disorders.... Read More
